# Nureca (NSE: NURECA) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/NURECA · Pivot · prices to 22 Oct 2026

Nureca (NSE: NURECA) closed at ₹338.50 on 22 Oct 2026, up 2.92% on the day. With a market capitalisation of ₹323 Cr, it ranks 2009th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Medical Devices.

At its last close the stock traded at 159.7× trailing earnings, against a return on equity of 1.2% in FY26. Over the past year the share price has risen 44.4%. Its 52-week range is ₹204.00 (30 Mar 2026) to ₹376.00 (30 Sep 2026); the last close is 10.0% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹40 Cr (+18.0% year on year) and net profit ₹3 Cr (+279.0%), on a consolidated basis. Promoters held 68.09% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹338.50 |
| Market cap | ₹323 Cr |
| P/E (trailing) | 159.7 |
| ROE | 1.2% (FY26) |
| ROCE | 3.4% (FY26) |
| Debt to equity | 0 |
| 52-week high | ₹376.00 (30 Sep 2026) |
| 52-week low | ₹204.00 (30 Mar 2026) |
| 1-year return | +44.4% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹40 Cr | +18.0% | ₹3 Cr | +279.0% | ₹3.21 |
| Q4 FY26 | ₹35 Cr | +11.6% | −₹6 Cr | −346.6% | −₹6.45 |
| Q3 FY26 | ₹40 Cr | +49.8% | ₹4 Cr | — | ₹3.91 |
| Q2 FY26 | ₹38 Cr | +21.0% | ₹4 Cr | — | ₹3.63 |
| Q1 FY26 | ₹34 Cr | +68.6% | ₹1 Cr | −51.2% | ₹0.81 |
| Q4 FY25 | ₹32 Cr | +87.0% | ₹2 Cr | — | ₹2.47 |
| Q3 FY25 | ₹26 Cr | +18.3% | −₹3 Cr | −1,747.1% | −₹2.80 |
| Q2 FY25 | ₹31 Cr | −0.5% | −₹0 Cr | −116.6% | −₹0.48 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹110 Cr | ₹1 Cr |
| FY24 | ₹92 Cr | −₹2 Cr |
| FY23 | ₹111 Cr | −₹8 Cr |
| FY22 | ₹256 Cr | ₹45 Cr |
| FY21 | ₹213 Cr | ₹46 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 68.09%
- Foreign institutions: 0.11%
- Domestic institutions: 0.24%
- Non-institutions: 31.57%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Medicamen Biotech](https://app.pivotnow.in/stock/MEDICAMEQ) | ₹266.50 | ₹361 Cr | 36.9 | — |
| [Astal  Lab](https://app.pivotnow.in/stock/ASTALLTD) | — | ₹358 Cr | — | — |
| [Aarey Drugs & Pharmaceuticals](https://app.pivotnow.in/stock/AAREYDRUGS) | ₹111.75 | ₹317 Cr | 80.4 | — |
| [Lyka Labs](https://app.pivotnow.in/stock/LYKALABS) | ₹82.64 | ₹299 Cr | — | — |
| [Bijoy Hans](https://app.pivotnow.in/stock/BIJHANS) | — | ₹292 Cr | — | — |
| [Astonea Labs](https://app.pivotnow.in/stock/ASTONEALAB) | — | ₹281 Cr | — | — |

## Questions and answers

### What is the share price of Nureca today?

Nureca (NSE: NURECA) last closed at ₹338.50 on 22 Oct 2026. Its 52-week high is ₹376.00 and its 52-week low is ₹204.00.

### What is the market cap of Nureca?

Nureca's market capitalisation is ₹323 Cr (₹323 Cr) at the 22 Oct 2026 close, ranking 2009th among the NSE companies Pivot tracks.

### What is the P/E ratio of Nureca?

Nureca trades at a trailing P/E of 159.7.

### What is the ROE and ROCE of Nureca?

Return on equity was 1.2% in FY26 and return on capital employed was 3.4% in FY26 (consolidated figures).

### Is Nureca a debt-free company?

Nureca is close to debt-free: its debt-to-equity ratio was 0 in FY26.

### What were Nureca's latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), Nureca reported revenue of ₹40 Cr, +18.0% year on year, and net profit of ₹3 Cr, +279.0% year on year.

### How has Nureca stock performed over the last year?

Nureca's share price has risen 44.4% over the past year, +10.6% over three months and −0.3% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Nureca?

As of 30 Jun 2026: promoters 68.09%, foreign institutions 0.11%, domestic institutions 0.24%, non-institutions 31.57%.

### Who are Nureca's competitors?

The listed Pharma & Healthcare companies closest to Nureca by market cap are Medicamen Biotech, Astal  Lab, Aarey Drugs & Pharmaceuticals, Lyka Labs, Bijoy Hans and Astonea Labs.

### Is Nureca a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Nureca's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on NURECA against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.